Live
FierceBiotechFledgling French biotech pens $128M deal for Kezar's preclinical protein degrader programFierceBiotechBridgeBio's muscle weakness data impress ahead of FDA filingFierceBiotechSmall molecules are ‘resurgent’ in orphan drug R&D: EvaluateFierceBiotechUltragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential winBioPharma DiveLilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compoundersEndpoints NewsA simpler form of DNA may be key to non-viral gene therapy, study suggestsEndpoints NewsBiotech startups use funding extensions to sidestep full capital roundsBioPharma DiveFDA to unify agency’s ‘fragmented’ safety surveillance systemEndpoints NewsSandoz reorg ahead of 'golden decade' for biosimilars; Sanofi to shed Latin America generics businessLonza NewsLonza divests Capsules & Health Ingredients business to Lone Star Funds for $3bn - Nutraceutical Business ReviewEndpoints News'Closed-loop' AI clinical care is coming soon, startups predictEndpoints NewsCompounders prescribing GLP-1s put pricing pressure on Novo, Lilly
FierceBiotech Mar 12, 2026

Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program

Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program

Original
Body unavailable. Use the original source.

Directory

59 All